Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 175

1.

Diet-Induced Growth Is Regulated via Acquired Leptin Resistance and Engages a Pomc-Somatostatin-Growth Hormone Circuit.

Löhr H, Hess S, Pereira MMA, Reinoß P, Leibold S, Schenkel C, Wunderlich CM, Kloppenburg P, Brüning JC, Hammerschmidt M.

Cell Rep. 2018 May 8;23(6):1728-1741. doi: 10.1016/j.celrep.2018.04.018.

PMID:
29742429
2.

Direct activation of chordoblasts by retinoic acid is required for segmented centra mineralization during zebrafish spine development.

Pogoda HM, Riedl-Quinkertz I, Löhr H, Waxman JS, Dale RM, Topczewski J, Schulte-Merker S, Hammerschmidt M.

Development. 2018 May 8;145(9). pii: dev159418. doi: 10.1242/dev.159418.

PMID:
29650589
3.

Biallelic CHP1 mutation causes human autosomal recessive ataxia by impairing NHE1 function.

Mendoza-Ferreira N, Coutelier M, Janzen E, Hosseinibarkooie S, Löhr H, Schneider S, Milbradt J, Karakaya M, Riessland M, Pichlo C, Torres-Benito L, Singleton A, Zuchner S, Brice A, Durr A, Hammerschmidt M, Stevanin G, Wirth B.

Neurol Genet. 2018 Jan 19;4(1):e209. doi: 10.1212/NXG.0000000000000209. eCollection 2018 Feb.

4.

Neurocalcin Delta Suppression Protects against Spinal Muscular Atrophy in Humans and across Species by Restoring Impaired Endocytosis.

Riessland M, Kaczmarek A, Schneider S, Swoboda KJ, Löhr H, Bradler C, Grysko V, Dimitriadi M, Hosseinibarkooie S, Torres-Benito L, Peters M, Upadhyay A, Biglari N, Kröber S, Hölker I, Garbes L, Gilissen C, Hoischen A, Nürnberg G, Nürnberg P, Walter M, Rigo F, Bennett CF, Kye MJ, Hart AC, Hammerschmidt M, Kloppenburg P, Wirth B.

Am J Hum Genet. 2017 Feb 2;100(2):297-315. doi: 10.1016/j.ajhg.2017.01.005. Epub 2017 Jan 26.

5.

An Ultraconserved Brain-Specific Enhancer Within ADGRL3 (LPHN3) Underpins Attention-Deficit/Hyperactivity Disorder Susceptibility.

Martinez AF, Abe Y, Hong S, Molyneux K, Yarnell D, Löhr H, Driever W, Acosta MT, Arcos-Burgos M, Muenke M.

Biol Psychiatry. 2016 Dec 15;80(12):943-954. doi: 10.1016/j.biopsych.2016.06.026. Epub 2016 Jul 14.

7.

RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells and sensitize tumors toward killing by CD8(+) T cells.

Duewell P, Steger A, Lohr H, Bourhis H, Hoelz H, Kirchleitner SV, Stieg MR, Grassmann S, Kobold S, Siveke JT, Endres S, Schnurr M.

Cell Death Differ. 2014 Dec;21(12):1825-37. doi: 10.1038/cdd.2014.96. Epub 2014 Jul 11. Erratum in: Cell Death Differ. 2014 Dec;21(12):161.

8.

Direct and indirect roles of Fgf3 and Fgf10 in innervation and vascularisation of the vertebrate hypothalamic neurohypophysis.

Liu F, Pogoda HM, Pearson CA, Ohyama K, Löhr H, Hammerschmidt M, Placzek M.

Development. 2013 Mar;140(5):1111-22. doi: 10.1242/dev.080226.

9.

Sim1a and Arnt2 contribute to hypothalamo-spinal axon guidance by regulating Robo2 activity via a Robo3-dependent mechanism.

Schweitzer J, Löhr H, Bonkowsky JL, Hübscher K, Driever W.

Development. 2013 Jan 1;140(1):93-106. doi: 10.1242/dev.087825.

10.

Integrating psychoeducation in a basic computer skills course for people suffering from social anxiety: participants' experiences.

Löhr HD, Rosenvinge JH, Wynn R.

J Multidiscip Healthc. 2011;4:311-9. doi: 10.2147/JMDH.S23691. Epub 2011 Aug 11.

11.

Dopaminergic and noradrenergic circuit development in zebrafish.

Schweitzer J, Lohr H, Filippi A, Driever W.

Dev Neurobiol. 2012 Mar;72(3):256-68. doi: 10.1002/dneu.20911. Review.

12.

Zebrafish in endocrine systems: recent advances and implications for human disease.

Löhr H, Hammerschmidt M.

Annu Rev Physiol. 2011;73:183-211. doi: 10.1146/annurev-physiol-012110-142320. Review.

PMID:
21314433
13.

Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease.

Tromm A, Bunganič I, Tomsová E, Tulassay Z, Lukáš M, Kykal J, Bátovský M, Fixa B, Gabalec L, Safadi R, Kramm HJ, Altorjay I, Löhr H, Koutroubakis I, Bar-Meir S, Stimac D, Schäffeler E, Glasmacher C, Dilger K, Mohrbacher R, Greinwald R; International Budenofalk Study Group.

Gastroenterology. 2011 Feb;140(2):425-434.e1; quiz e13-4. doi: 10.1053/j.gastro.2010.11.004. Epub 2010 Nov 9.

PMID:
21070781
14.
15.

Multiple, parallel cellular suicide mechanisms participate in photoreceptor cell death.

Lohr HR, Kuntchithapautham K, Sharma AK, Rohrer B.

Exp Eye Res. 2006 Aug;83(2):380-9. Epub 2006 Apr 19. Erratum in: Exp Eye Res. 2006 Dec;83(6):1522.

PMID:
16626700
16.

Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy.

Böcher WO, Schuchmann M, Link R, Hillenbrand H, Rahman F, Sprinzl M, Mudter J, Löhr HF, Galle PR.

Liver Int. 2006 Apr;26(3):319-25.

PMID:
16584394
17.

Cone opsin mislocalization in Rpe65-/- mice: a defect that can be corrected by 11-cis retinal.

Rohrer B, Lohr HR, Humphries P, Redmond TM, Seeliger MW, Crouch RK.

Invest Ophthalmol Vis Sci. 2005 Oct;46(10):3876-82.

PMID:
16186377
18.

Downregulation of cone-specific gene expression and degeneration of cone photoreceptors in the Rpe65-/- mouse at early ages.

Znoiko SL, Rohrer B, Lu K, Lohr HR, Crouch RK, Ma JX.

Invest Ophthalmol Vis Sci. 2005 Apr;46(4):1473-9.

PMID:
15790918
19.

Phenotype and function of monocyte derived dendritic cells in chronic hepatitis B virus infection.

Tavakoli S, Schwerin W, Rohwer A, Hoffmann S, Weyer S, Weth R, Meisel H, Diepolder H, Geissler M, Galle PR, Löhr HF, Böcher WO.

J Gen Virol. 2004 Oct;85(Pt 10):2829-36.

PMID:
15448344
20.

Multidestructive pathways triggered in photoreceptor cell death of the rd mouse as determined through gene expression profiling.

Rohrer B, Pinto FR, Hulse KE, Lohr HR, Zhang L, Almeida JS.

J Biol Chem. 2004 Oct 1;279(40):41903-10. Epub 2004 Jun 24.

21.

Interleukin-2 has no additional therapeutic efficacy in the retreatment of patients with chronic hepatitis C that had not responded to interferon-alpha plus ribavirin.

Barreiros AP, Schlaak JF, Gerken G, Galle PR, Löhr HF.

Eur J Clin Invest. 2003 Jul;33(7):628-9. No abstract available.

PMID:
12814401
22.
23.

Individual and common antigen-recognition sites of liver-derived T cells in patients with autoimmune hepatitis.

Löhr HF, Pingel S, Weyer S, Fritz T, Galle PR.

Scand J Immunol. 2003 Apr;57(4):384-90.

24.

Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase.

van Nunen AB, Hansen BE, Suh DJ, Löhr HF, Chemello L, Fontaine H, Heathcote J, Song BC, Janssen HL, de Man RA, Schalm SW.

Gut. 2003 Mar;52(3):420-4.

25.

Pyruvate dehydrogenase specific T cells in primary biliary cirrhosis show restricted antigen recognition sites.

Pingel S, Arenz M, Meyer zum Büschenfelde KH, Löhr HF.

Liver. 2002 Aug;22(4):308-16.

PMID:
12296964
26.

Reduced virus specific T helper cell induction by autologous dendritic cells in patients with chronic hepatitis B - restoration by exogenous interleukin-12.

Löhr HF, Pingel S, Böcher WO, Bernhard H, Herzog-Hauff S, Rose-John S, Galle PR.

Clin Exp Immunol. 2002 Oct;130(1):107-14.

27.

[Autoimmune hepatitis and overlap syndrome: therapy].

Löhr HF.

Praxis (Bern 1994). 2002 Aug 21;91(34):1347-51. Review. German.

PMID:
12233265
28.

Comparison of Gd-BOPTA and Gd-DOTA for peripheral CE-MRA: a double-blind clinical study.

Lohr HA, Froehlich JM, Pfyffer M, Bader CW, Zollikofer CL, Wentz KU.

Acad Radiol. 2002 Aug;9 Suppl 2:S421-4. No abstract available.

PMID:
12188295
30.

Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or without interleukin-2 in patients with chronic hepatitis B.

Dahmen A, Herzog-Hauff S, Böcher WO, Galle PR, Löhr HF.

J Med Virol. 2002 Apr;66(4):452-60.

PMID:
11857521
31.

Induction of strong hepatitis B virus (HBV) specific T helper cell and cytotoxic T lymphocyte responses by therapeutic vaccination in the trimera mouse model of chronic HBV infection.

Böcher WO, Dekel B, Schwerin W, Geissler M, Hoffmann S, Rohwer A, Arditti F, Cooper A, Bernhard H, Berrebi A, Rose-John S, Shaul Y, Galle PR, Löhr HF, Reisner Y.

Eur J Immunol. 2001 Jul;31(7):2071-9.

33.

Long-term management and prognosis of autoimmune hepatitis (AIH): a single center experience.

Kanzler S, Löhr H, Gerken G, Galle PR, Lohse AW.

Z Gastroenterol. 2001 May;39(5):339-41, 344-8.

PMID:
11413913
34.

[Lymphoma-simulating presentation of focal nodular hyperplasia (FNH) of the liver].

Schmitz D, Köhler HH, Heussel CP, Löhr HF, Galle PR.

Z Gastroenterol. 2001 Mar;39(3):219-24. German.

PMID:
11324139
35.

Duration of immunosuppressive therapy in autoimmune hepatitis.

Kanzler S, Gerken G, Löhr H, Galle PR, Meyer zum Büschenfelde KH, Lohse AW.

J Hepatol. 2001 Feb;34(2):354-5. No abstract available.

PMID:
11281572
36.

[Artificial pacemaker implantation].

Löhr H.

Chirurg. 2001 Feb;72(2):203-19; quiz 220-1. German. No abstract available.

PMID:
11253685
37.

[Retrospective cohort study of lamivudine therapy in patients with chronic hepatitis B].

Teuber G, Löhr HF, Kallinowski B, Berg T, Müller R, Zeuzem S.

Dtsch Med Wochenschr. 2001 Feb 2;126(5):97-102. German.

PMID:
11225393
38.
39.

How long to treat chronic hepatitis B virus infection with lamivudine?

Löhr HF, Schlaak JF, Lohse AW, Böcher WO, Kanzler S, Ibe M, Galle PR.

J Hepatol. 2000 Aug;33(2):343. No abstract available.

PMID:
10952257
40.

The gp130-stimulating designer cytokine hyper-IL-6 promotes the expansion of human hematopoietic progenitor cells capable to differentiate into functional dendritic cells.

Bernhard H, Lohmann M, Batten WY, Metzger J, Löhr HF, Peschel C, zum Büschenfelde KM, Rose-John S.

Exp Hematol. 2000 Apr;28(4):365-72.

PMID:
10781894
41.

Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen.

Rahman F, Dahmen A, Herzog-Hauff S, Böcher WO, Galle PR, Löhr HF.

Hepatology. 2000 Feb;31(2):521-7.

PMID:
10655280
42.
43.

[Synthesis of tumor affinity label Yb-169- and Y-90- porphyrin complexes and animal experimental investigations with various Yb-169-porphyrins].

Schomäcker K, Gaidouk MI, Rumyantseva VD, Fischer T, Löhr H, Salditt S, Liebenhoff S, Schicha H.

Nuklearmedizin. 1999;38(7):285-91. German.

PMID:
10599068
44.

Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis.

Kanzler S, Weidemann C, Gerken G, Löhr HF, Galle PR, Meyer zum Büschenfelde KH, Lohse AW.

J Hepatol. 1999 Oct;31(4):635-40.

PMID:
10551386
45.

The viral clearance in interferon-treated chronic hepatitis C is associated with increased cytotoxic T cell frequencies.

Löhr HF, Schmitz D, Arenz M, Weyer S, Gerken G, Meyer zum Büschenfelde KH.

J Hepatol. 1999 Sep;31(3):407-15.

PMID:
10488697
46.

HBV-specific immune defect in chronic hepatitis B (CHB) is correlated with a dysregulation of pro- and anti-inflammatory cytokines.

Schlaak JF, Tully G, Löhr HF, Gerken G, Meyer zum Büschenfelde KH.

Clin Exp Immunol. 1999 Mar;115(3):508-14.

47.

The presence of high amounts of HBV-DNA in serum is associated with suppressed costimulatory effects of interleukin 12 on HBV-induced immune response.

Schlaak JF, Tully G, Löhr HF, Gerken G, Meyer zum Büschenfelde KH.

J Hepatol. 1999 Mar;30(3):353-8.

PMID:
10190714
48.

Quantitative and functional analysis of core-specific T-helper cell and CTL activities in acute and chronic hepatitis B.

Löhr HF, Krug S, Herr W, Weyer S, Schlaak J, Wölfel T, Gerken G, Meyer zum Büschenfelde KH.

Liver. 1998 Dec;18(6):405-13.

PMID:
9869395
49.
50.

The cellular immune responses induced in the follow-up of interferon-alpha treated patients with chronic hepatitis C may determine the therapy outcome.

Löhr HF, Gerken G, Roth M, Weyer S, Schlaak JF, Meyer zum Büschenfelde KH.

J Hepatol. 1998 Oct;29(4):524-32.

PMID:
9824260

Supplemental Content

Support Center